This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mallinckrodt Ends Enrollment in Phase III for Terlipressin
by Zacks Equity Research
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1
by Zacks Equity Research
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.
Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.
BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
by Zacks Equity Research
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
by Zacks Equity Research
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
by Zacks Equity Research
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Will Merus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Merus.
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
by Zacks Equity Research
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
by Zacks Equity Research
Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.
Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara
by Zacks Equity Research
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Merus Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merus has been struggling lately, but the selling pressure may be coming to an end soon.
Merus' Antibody Candidate in Phase II Breast Cancer Study
by Zacks Equity Research
Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.
Merus (MRUS) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Merus (MRUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.
Incyte/Merus Ink Collaboration for Bispecific Antibodies
by Zacks Equity Research
Incyte (INCY) entered into an agreement with Merus (MRUS) to discover and develop bispecific antibodies using the latter's proprietary Biclonics technology platform.